Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out - Reuters

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPaTdmamc4QU9IekYyT2hOdlVOdlowVjFnZE84b29mN3RuNXFUMURRaUEwTUkzMEwxVllJT3NzdHo3ZjNoYmJmZk41QUpkSTRacmdCd2ZpSVkxdE1icFVXUVVOVUExblRobUpuT2FUSV8td3dCUS00dm5NYU5LYmFTTEdLT0lhQm9naEczT2lySU9GSS1ZUFpEZnNCemFVUk9lejMxR2RBVFNScFBRamlpbEpjQU1iX0RmVjlJVXZJR0k2T2dGZkJWVWItaDY4czE3YkdTT1Fab05tUQ?oc=5" target="_blank">Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's rival.

Novo Nordisk shares fell more than 15% on Monday, wiping away the last gains Wegovy’s launch had brought, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly’s tirzepatide in a trial.

Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's rival.

Novo Nordisk ha sufrido una nueva caída en Bolsa tras anunciar que los ensayos clínicos de su nuevo medicamento contra la obesidad, CagriSema, no alcanzaron el criterio principal de efectividad frente a su competidor Tirzepatida, comercializado por Eli Lilly.